Israel Englander Kaleido Biosciences, Inc. Transaction History

Millennium Management LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.05 - $1.7 $3,850 - $130,910	-77,006 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.3 - $2.7 $63,312 - $131,495	-48,702 Reduced 38.74%	77,006 $127,000
Q4 2021 Feb 14, 2022	BUY	$2.39 - $6.02 $300,442 - $756,762	125,708 New	125,708 $300,000
Q2 2021 Aug 16, 2021	SELL	$5.82 - $8.72 $79,530 - $119,158	-13,665 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$7.2 - $16.82 $213,832 - $499,537	-29,699 Reduced 68.49%	13,665 $111,000
Q4 2020 Feb 16, 2021	BUY	$5.77 - $11.33 $250,210 - $491,314	43,364 New	43,364 $395,000
Q2 2020 Aug 14, 2020	SELL	$4.62 - $8.01 $58,479 - $101,390	-12,658 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$3.62 - $9.49 $45,821 - $120,124	12,658 New	12,658 $78,000
Q4 2019 Feb 14, 2020	SELL	$5.02 - $8.87 $107,458 - $189,871	-21,406 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$6.74 - $11.3 $49,087 - $82,297	-7,283 Reduced 25.39%	21,406 $161,000
Q2 2019 Aug 15, 2019	SELL	$11.25 - $18.1 $2.3 Million - $3.71 Million	-204,812 Reduced 87.71%	28,689 $333,000
Q2 2019 Aug 14, 2019	BUY	$11.25 - $18.1 $1.64 Million - $2.63 Million	145,392 Added 165.01%	233,501 $6.13 Million
Q1 2019 May 14, 2019	BUY	$12.71 - $15.0 $1.12 Million - $1.32 Million	88,109 New	88,109 $1.28 Million

2.65K

Ticker KLDO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,622,600
Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.